1.4800 +0.03 (2.07%)
After hours: 7:58PM EST
|Bid||1.4500 x 27000|
|Ask||1.4800 x 42300|
|Day's range||1.4000 - 1.6200|
|52-week range||0.8500 - 2.7500|
|Beta (5Y monthly)||1.99|
|PE ratio (TTM)||N/A|
|Earnings date||02 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.67|
Thank you for joining us for TherapeuticsMD fourth-quarter 2020 financial results conference call. This morning, TherapeuticsMD issued a press release announcing our fourth-quarter financial results. On today's call from TherapeuticsMD are Chief Executive Officer Robert Finizio, Chief Financial Officer James D'Arecca, Chief Commercial Officer Dawn Halkuff, and Chief Strategy and Performance Officer Mitchell Krassan.
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50.00% and 6.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
TXMD net product revenue in 2020 increased 84% over 2019; conference call at 8:30am ET today to discuss financial and business results for 2020.